DESCRIPTION:
This book provides a comprehensive review of innovative diagnostic methods for prostate cancer, with a particular emphasis on the development of PET radiopharmaceuticals. The author has had the privilege to introduce several tracers into clinical routine practice, including Na18F, 18F-FCH, 18F-FACBC, 68Ga-PSMA11, 18F-PSMA-1007, and 18F-DCFPyL. Thus, indications in various prostate cancer subgroups are discussed in detail, weighing the pros and cons in clinical practice. In the authors´ practice radiation therapy has been more important and surgical applications therefore, PET based dose planning is presented in detail. Furthermore, the author has closely followed the development of radiopharmaceutical treatments, particularly in the context of bone pain palliation using radiopharmaceuticals, such as 89SrCl2, 186ReHEDP, 153SmEDTMP, 117mSnDTPA, and 223RaCl2, and targeted treatments (177Lu-PSMSA-617, 177Lu-PSMA-I&T and 225Ac-PSMA).
Thanks to his experience, the author facilitated the set-up of targeted treatments in various countries: Baltic and Nordic countries, elsewhere in Europe, North America (Canada), and Africa (e.g. Ghana). The author""s involvement in promoting therapy tourism to Finland further highlights his breadth of knowledge and practical experience.
This book offers valuable insights into the evolving landscape of diagnostic methods and radiopharmaceutical treatments for prostate cancer. With the author""s extensive experience and contributions to the field, readers can gain a comprehensive understanding of these advancements and their implications in clinical practice.
CONTENTS:
Introduction: Prostate Cancer from the Point of View of the Author and the History of Imaging
Experimental
Integrated Summary of Research on Radioiodinated Estramustine Phosphate and Estramustine Binding Protein Antibody in Prostate Cancer Treatment
Clinical Diagnostics
Summary of Diagnostic Accuracy of 18F-Fluorocholine PET/CT in Prostate Cancer Staging
Overview of 18F-NaF PET/CT Imaging
18F-Fluciclovine (18F-FACBC) Positron Emission Tomography in Prostate Cancer
PSMA-PET in Prostate Cancer
18F-FLT PET/CT in Prostate Adenocarcinoma
18F-FDHT-PET Imaging in the Management of Hormone-Dependent Prostate Cancer
Immunoscintigraphy and Radioimmunotherapy of Prostate Cancer Including Own Personal Journey: Anti-PAP and Anti-PSMA Antibodies
Briefly About Radiation Therapy
PET/CT for Radiation Therapy Planning of Prostate Cancer
Brief Overview of Prostate Cancer Treatment Modalities
Targeted Therapy (Radionuclides)
Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Lu-177-PSMA Treatment in Prostate Cancer
Clinical Trials
Clinical Experience in 225Ac-PSMA
Multicenter Trials of Prostate Radioligand Therapy (PRLT) in Castration-Resistant Cancer
Meta-Analyses and Systematic Reviews (Own Experience) in Prostate Cancer
Own Cancer Career
Own History of Cancer Suspicions
Public Appearance Because of Nuclear Oncology (Pictorial Essay)
